- Restoring Metabolic Functions Topically in the Gut Lumen
- Validated Platform with 3 Preclinical Proof of Concepts
- Established as a pivate company (AG) in Basel in 2019
- Secured a Partnership with Nestlé Health Science for one asset
- Raised CHF 7.4M in equity and non-dilutive funding
- Raising Series A
Products, services, technology
Our pipeline is focused on digestive therapies for Exocrine Pancreatic Insufficiency, Acquired Lactase Deficiency, Congenital Sucrase Deficiency, and Phenylketonuria. Additionally, our enzyme therapeutics platform can be applied to Systemic Enzyme Replacement Therapies and Oncology.
Cooperation possibilities
Our validated platform can generate multiple assets for Intoxication-Type Inborn Errors of Metabolism, a family of rare diseases like PKU, Tyrosinemia, MSUD, CSID, Homocystinuria.
With an excellent partnering track record , Perseo is open to collaboration with Pharma to develop these new assets.
- http://www.perseo-pharma.com
- +41 76 423 12 29
- yves.dudal@perseo-pharma.com
- Yves Dudal
